Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases (BOLT+BMT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01852370|
Recruitment Status : Enrolling by invitation
First Posted : May 13, 2013
Last Update Posted : November 8, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Severe Combined Immunodeficiency (SCID) Immunodeficiency With Predominant T-cell Defect, Unspecified Severe Chronic Neutropenia Chronic Granulomatous Disease (CGD) Hyper IgE Syndromes Hyper IgM Deficiencies Wiskott-Aldrich Syndrome Mendelian Susceptibility to Mycobacterial Disease Common Variable Immune Deficiency (CVID)||Biological: CD3/CD19 negative allogeneic hematopoietic stem cells||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors|
|Actual Study Start Date :||June 20, 2013|
|Estimated Primary Completion Date :||November 2023|
|Estimated Study Completion Date :||November 2024|
All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
- Safety: Death [ Time Frame: Up to 2 years post stem cell transplant ]How many, if any, patients die.
- Safety: Engraftment syndrome [ Time Frame: Up to 2 years post stem cell transplant ]How many, if any, patients develop engraftment syndrome.
- Safety: Engraftment failure [ Time Frame: Up to 2 years post stem cell transplant ]How many patients, if any, develop engraftment failure.
- Safety: Rituximab [ Time Frame: Up to 2 years post stem cell transplant ]The number of grade 4 and 5 events potentially related to rituximab.
- Efficacy: BOS score [ Time Frame: 1 year post stem cell transplant ]Bronchiolitis Obliterans Syndrome (BOS) score for all patients who receive both lungs and stem cell transplants.
- Efficacy: T-cell chimerism [ Time Frame: 1 year post stem cell transplant ]The number of patients who have ≥ 25% donor T-cell chimerism.
- Efficacy: Myeloid chimerism [ Time Frame: 1 year post stem cell transplant ]The number of patients with myeloid disorders (e.g. CGD) who attain ≥ 10% myeloid chimerism.
- Efficacy: B-cell chimerism [ Time Frame: 1 year post stem cell transplant ]The number of patients with B-cell disorders who attain ≥ 10% B-cell chimerism.
- Feasibility of meeting BMT eligibility critieria [ Time Frame: Up to 2 years post stem cell transplant ]The number of patients who are able to proceed to BMT within 6 months following lung transplant.
- Tolerance [ Time Frame: Up to 2 years post stem cell transplant ]Development of tolerance to both the host and pulmonary graft.
- Long-term complications [ Time Frame: Up to 2 years post stem cell transplant ]Long-term complications of combined solid organ and BMT.
- Graft failure [ Time Frame: Up to 2 years post stem cell transplant ]The number of patients who develop graft failure.
- Acute cellular rejection [ Time Frame: Up to 2 years post stem cell transplant ]The number of patients who develop acute cellular rejection.
- Acute graft-versus-host disease (GVHD) [ Time Frame: Up to 2 years post stem cell transplant ]The number of patient who develop acute graft-versus-host disease (GVHD).
- Chronic graft-versus-host disease (GVHD) [ Time Frame: Up to 2 years post stem cell transplant ]The number of patient who develop chronic graft-versus-host disease (GVHD).
- Ability to withdraw immunosuppression [ Time Frame: 1 year post stem cell transplant ]The number of patients who are able to start immunosuppression withdrawal.
- Time to withdraw immunosuppression [ Time Frame: Up to 2 years post stem cell transplant ]Time from BMT to withdrawal of immunosuppression.
- Pathogen-specific immunity [ Time Frame: Up to 2 years post stem cell transplant ]Time from BMT to independence from treatment dose antimicrobial drugs.
- Lymphocyte count - for T-cell lymphopenias [ Time Frame: 1 year post stem cell transplant ]The number of patients who are able to achieve an age adjusted, low limit normal range lymphocyte count.
- Chronic lung allograft dysfunction [ Time Frame: 1 year post lung transplant ]The number of patients who develop chronic lung allograft dysfunction post-lung transplant for all subjects, lung only and lung+stem cell transplant.
- Allograft failure [ Time Frame: 1 year post lung transplant ]The number of patients who develop allograft failure post-lung transplant for all subjects, lung only and lung+stem cell transplant.
- Rituximab related adverse events [ Time Frame: From the time of the first dose of rituximab up to the start of BMT conditioning. ]The number of grade 4 or 5 adverse events possibly related to the use of rituximab.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||5 Years to 45 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject and/or parent guardian must be able to understand and provide informed consent.
- Male or female, 5 through 45 years old, inclusive, at the time of informed consent.
Patients must have evidence of an underlying primary immunodeficiency for which BMT is clinically indicated.
Examples of such diseases include, but are not limited to:
- Severe Combined Immunodeficiency
- Combined immunodeficiency with defects in T-cell-mediated immunity, including Omenn syndrome and DiGeorge Syndrome
- Severe Chronic Neutropenia
- Chronic Granulomatous Disease
- Hyper IgE Syndrome or Job Syndrome
- CD40 or CD40L deficiency
- Wiskott-Aldrich Syndrome
- Mendelian Susceptibility to Mycobacterial Disease 
- GATA2 Associated Immunodeficiency NOTE: A genetic diagnosis is recommended, but not required.
- Patients must have evidence of end-stage lung disease and be candidates for bilateral orthotopic lung transplant as determined by the lung transplant team.
- GFR ≥ 50 mL/min/1.73 m2.
- AST, ALT ≤ 4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL, normal INR.
- Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%.
- Negative pregnancy test for females >10 years old or who have reached menarche, unless surgically sterilized.
- All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defect.
- Subject and/or parent guardian will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting.
Individuals who meet any of these criteria are not eligible for this study:
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
- Patients who have underlying malignant conditions.
- Patients who have non-malignant conditions not requiring hematopoietic stem cell transplantation.
- HIV positive by serology or PCR, HTLV positive by serology.
- Females who are pregnant or who are lactating.
- Allergy to DMSO or any other ingredient used in the manufacturing of the stem cell product.
- Uncontrolled pulmonary infection, as determined by radiographic findings and/or significant clinical deterioration. NOTE: Pulmonary colonization with multiple organisms is common, and will not be considered an exclusion criterion.
- Uncontrolled systemic infection, as determined by the appropriate confirmatory testing e.g. blood cultures, PCR testing, etc.
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of transplant.
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Eligibility Criteria to proceed to Bone Marrow Transplant
- GFR ≥ 50 mL/min/1.73 m2.
- AST, ALT ≤ 4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL.
- Cardiac ejection fraction ≥ 40% or shortening fraction of at least 26%.
- HIV negative by serology and PCR.
- HTLV serology negative.
- FVC and FEV1 ≥40% predicted for age and SpO2 of >90% at rest on room air AND with clearance by the lung transplant team.
- Absence of uncontrolled infection as determined by positive blood cultures and radiographic progression of previous sites in particular pulmonary densities during the past 2 weeks prior to chemotherapy.
- Absence of clinically significant Acute Cellular Rejection (A2-A4 and/or B2R rejection).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01852370
|United States, Pennsylvania|
|Children's Hospital of Pittsburgh of UPMC|
|Pittsburgh, Pennsylvania, United States, 15224|
|Principal Investigator:||Paul Szabolcs, MD||Division of BMT and Cellular Therapy, Children's Hospital of Pittsburgh of UPMC|
|Responsible Party:||Paul Szabolcs, Chief, Division of Blood and Marrow Transplant, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh|
|Other Study ID Numbers:||
|First Posted:||May 13, 2013 Key Record Dates|
|Last Update Posted:||November 8, 2022|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Bone Marrow Transplantation
Granulomatous Disease, Chronic
Severe Combined Immunodeficiency
Immunologic Deficiency Syndromes
Common Variable Immunodeficiency
Immune System Diseases
Phagocyte Bactericidal Dysfunction
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Primary Immunodeficiency Diseases
Infant, Newborn, Diseases
DNA Repair-Deficiency Disorders
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Gram-Positive Bacterial Infections